2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2015
Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer
Ruel E, Thomas S, Dinan MA, Perkins JM, Roman SA, Sosa JA. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer. Endocrine 2015, 52: 579-586. PMID: 26708045, PMCID: PMC4880494, DOI: 10.1007/s12020-015-0826-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaCarcinoma, PapillaryCombined Modality TherapyDatabases, FactualFemaleHumansIodine RadioisotopesKnowledgeLymph NodesLymphatic MetastasisMaleMiddle AgedPostoperative PeriodPrognosisRadiotherapy DosageRisk FactorsSurvival AnalysisThyroid Cancer, PapillaryThyroid NeoplasmsThyroidectomyConceptsNegative lymph nodesPapillary thyroid cancerLow-risk papillary thyroid cancerLymph nodesCN0 patientsRAI useThyroid cancerPostoperative radioactive iodine administrationTrue nodal statusExcised lymph nodesLow-risk patientsLymph node statusRadioactive iodine administrationNegative surgical marginsOdds of receiptSurgical pathology specimensCut-point analysisPN0 patientsPN0 statusPostoperative RAIRAI administrationCervical lymphMultivariable adjustmentTotal thyroidectomyNodal statusPresence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer
Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal Of Clinical Oncology 2015, 33: 2370-2375. PMID: 26077238, DOI: 10.1200/jco.2014.59.8391.Peer-Reviewed Original ResearchConceptsCervical lymph node metastasisAge 45 yearsLymph node metastasisPapillary thyroid cancerMetastatic lymph nodesAmerican Joint CommitteeOverall survivalNode metastasisMetastatic nodesLymph nodesNodal metastasisThyroid cancerJoint CommitteeAssociation of OSPatients age 45 yearsNational Cancer Data BaseCurrent American Joint CommitteeMore positive nodesLow-risk diseasePresence of lymphAdditional mortality riskPositive nodesPreoperative screeningAdult patientsSEER databaseImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years
Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 115-121. PMID: 25337927, PMCID: PMC5399499, DOI: 10.1210/jc.2014-3039.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer patientsTotal thyroidectomyOverall survivalThyroid cancer patientsImpact of extentYears of ageCancer patientsNational Cancer Data BaseUnadjusted overall survivalLymph node diseaseExtent of resectionEnd Results (SEER) datasetAdult patientsClinical characteristicsExcellent prognosisNode diseasePathologic factorsImproved survivalThyroid lobectomyTumor sizeCurrent guidelinesMultivariable modelingLobectomyMAIN OUTCOMEThyroidectomy
2014
Robotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term Outcomes
Abdelgadir Adam M, Speicher P, Pura J, Dinan MA, Reed SD, Roman SA, Sosa JA. Robotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term Outcomes. Annals Of Surgical Oncology 2014, 21: 3859-3864. PMID: 24934584, PMCID: PMC4519825, DOI: 10.1245/s10434-014-3838-8.Peer-Reviewed Original ResearchConceptsShort-term outcomesRobotic thyroidectomyMultivariable analysisOpen thyroidectomyOpen surgeryThyroid cancerPatterns of useRobotic casesRobotic groupRobotic surgeryThyroidectomy-specific complicationsUnderwent open surgeryNational Cancer DatabaseLong-term outcomesLength of stayMulti-institutional studyNon-significant increaseMore Asian patientsTotal thyroidectomyUnderwent lobectomyUnderwent thyroidectomyLymph nodesSurgery useAsian patientsPositive marginsImpact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States
Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States. Annals Of Surgical Oncology 2014, 21: 3515-3521. PMID: 24841347, PMCID: PMC4510956, DOI: 10.1245/s10434-014-3769-4.Peer-Reviewed Original ResearchConceptsNonfunctional pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsExtent of surgerySmall Nonfunctional Pancreatic Neuroendocrine TumorsFive-year OSOverall survivalMalignant potentialNeuroendocrine tumorsNational Cancer Data BaseLymph node dissectionLymph node resectionKaplan-Meier analysisType of surgeryLog-rank testUncertain malignant potentialImpact of extentNode dissectionNode resectionTotal pancreatectomyPatient characteristicsRegional lymphRegional lymphadenectomySurgical resectionImproved survivalDistant metastasisRedistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005. Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.Peer-Reviewed Original ResearchConceptsCell lung cancerTotal health care costsHealth care costsPositron emission tomographyProportion of patientsRate of surgeryMedicare beneficiariesLung cancerCare costsEmission tomographySurgical resectionInpatient costsRetrospective cohort studyYear of diagnosisMain outcome measuresCohort studyTreatment patternsOutcome measuresRadiation therapyChemotherapyPatientsRadiotherapyStudy periodCancerMedicare approval